The US is the bigger Biosimilars market: $15.5 Bn against $3 Bn in 2023, about 5.2 times as large.
China grows faster: 26.4% a year, against 22.9%. The gap still grows from $12.5 Bn to $91 Bn by 2033.
Clinical research: 351 active trials in the US, 34 in China.
| Measure |  US |  China |
|---|---|---|
| Market size, 2023 | $15.5 Bn | $3 Bn |
| Market size, 2033 projected | $121.8 Bn | $30.9 Bn |
| Growth a year (CAGR) | 22.9% | 26.4% |
| Money added, 2023–2033 | $106.3 Bn | $27.9 Bn |
| Share of the world market | 42% | 8% |
| Size rank of 24 countries | #1 | #2 |
| Market per person, 2023 | $45 | $2.11 |
| Active clinical trials | 351 | 34 |
| Full report | US report | China report |
Year by year, 2023 to 2033
US China · values between 2023 and 2033 are projected from the 2023 size and the CAGR.
Quick answers
Which is bigger in Biosimilars, US or China?
The US is the bigger Biosimilars market: $15.5 Bn against $3 Bn in 2023, about 5.2 times as large.
Which grows faster in Biosimilars, US or China?
China grows faster: 26.4% a year, against 22.9%. The gap still grows from $12.5 Bn to $91 Bn by 2033.
More Biosimilars comparisons
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov (fetched 10 Nov 2026); found by search words, so counts are a guide. Population: World Bank.